Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, describes how his team built a predictive algorithm using machine learning to predict the development of posttraumatic stress disorder (PTSD).
Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, describes how his team built a predictive algorithm using machine learning to predict the development of posttraumatic stress disorder (PTSD).
Transcript
How does the predictive algorithm constructed by your lab use machine learning to predict PTSD risk?
So, PTSD risk is really dependent on multiple factors. There’s many different things that can cause a deleterious outcome after trauma. And even the outcomes that you have vary between individuals, whether it’s PTSD, depression, problems with sleep, problems with memory, problems with arousal. So we constructed an algorithm that uses electronic medical records and simple information about the patient’s objective distress to predict how the patient is going to do over the next 12 months.
We built it and validated it in 2 independent data sets. One, the Grady trauma project from Emory Hospital, roughly 220 subjects, and then we validated it in our own sample collected at Bellevue Hospital in New York City. We got a predictive accuracy of roughly 90% for predicting chronic PTSD, and we replicated that independently in the Bellevue data set.
The sources of data include information on immune response, metabolic response, all the early biological changes that are associated with the onset of PTSD and depression that cause changes in things like sleep patterns, memory, arousal.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More